Abstract:OBJECTIVE-Glycogen synthase kinase (GSK)-3 beta plays an important role in cardiomyopathies. Cardiac-specific metallothionein-overexpressing transgenic (MT-TG) mice were highly resistant to diabetes-induced cardiomyopathy. Therefore, we investigated whether metallothionein cardiac protection against, diabetes is mediated by inactivation of GSK-3 beta. RESEARCH DESIGN AND METHODS-Diabetes was induced with streptozotocin in both MT-TG and wild-type mice. Changes of energy metabolism-related molecules, lipid accumulation, inflammation, nitrosative damage, and fibrotic remodeling were examined in the hearts of diabetic mice 2 weeks, 2 months, and 5 months after the onset, of diabetes with Western blotting, RT-PCR, and immunohistochemical assays. RESULTS-Activation (dephosphorylation) of GSK-3 beta was evidenced in the hearts of wild-type diabetic mice but not MT-TG diabetic mice. Correspondingly, cardiac glycogen synthase phosphorylation, hexokinase II, PPAR alpha, and PGC-1 alpha expression, which mediate glucose and lipid metabolisms, were significantly changed along with cardiac lipid accumulation, inflammation (TNF-alpha, plasminogen activator inhibitor 1 [PAI-1], and intracellular adhesion molecule 1 [ICAM-1]), nitrosative damage (3-nitrotyrosin accumulation), and fibrosis in the wild-type diabetic mice. The above pathological changes were completely prevented either by cardiac metallothionein in the MT-TG diabetic mice or by inhibition of GSK-3 beta activity in the wild-type diabetic mice with a GSK-3 beta-specific inhibitor. CONCLUSIONS-These results suggest that activation of GSK-3 beta plays a critical role in diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Metallothionein inactivation of GSK-3 beta plays a critical role in preventing diabetic cardiomyopathy. Diabetes 58:13911402,2009

Hypoxia‐inducible Factor 1α is Critically Involved in Metallothionein Protection Against Diabetic Cardiomyopathy

Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions.

Activation of HIF-1 by Metallothionein Contributes to Cardiac Protection in the Diabetic Heart.

Endothelial Overexpression of Metallothionein Prevents Diabetes Mellitus-Induced Impairment in Ischemia Angiogenesis Via Preservation of HIF-1α/SDF-1/VEGF Signaling in Endothelial Progenitor Cells

Cardiac-Specific Overexpression of HIF-1α Prevents Deterioration of Glycolytic Pathway and Cardiac Remodeling in Streptozotocin-Induced Diabetic Mice

Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice

Metallothionein Alleviates Cardiac Dysfunction in Streptozotocin-Induced Diabetes: Role of Ca2+ Cycling Proteins, NADPH Oxidase, Poly(adp-Ribose) Polymerase and Myosin Heavy Chain Isozyme

Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury.

Diabetes- and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection.

Metallothionein Prevents Diabetes-Induced Deficits in Cardiomyocytes by Inhibiting Reactive Oxygen Species Production.

Metallothionein Prevents Intermittent Hypoxia-Induced Cardiac Endoplasmic Reticulum Stress and Cell Death Likely Via Activation of Akt Signaling Pathway in Mice.

Attenuation of AngII‐induced Early Cell Death by MT Results in a Prevention of the Late Development of Cardiomyopathy

Intermittent Hypoxia-Induced Cardiomyopathy and Its Prevention by Nrf2 and Metallothionein.

Metallothionein as an Adaptive Protein Prevents Diabetes and its Toxicity

The Adaptive Immune Role Of Metallothioneins In The Pathogenesis Of Diabetic Cardiomyopathy: Good Or Bad

Macrophage Migration Inhibitory Factor Deficiency Augments Cardiac Dysfunction in Type 1 Diabetic Murine Cardiomyocytes

Metallothionein As a Compensatory Component Prevents Intermittent Hypoxia-Induced Cardiomyopathy in Mice.

Stable Overexpression of Human Metallothionein-Iia in A Heart-Derived Cell Line Confers Oxidative Protection

Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.

Nrf2 Protects From Intermittent Hypoxia-induced Cardiomyopathy via Metallothionein-dependent and Independent Mechanisms

Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling.